Pentwater Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Pentwater Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24,000	Closed	-$1.6M	–	256
2021 Q3	$1.6M	Sell	24,000 -16,000	-40%	-$923K	0.02%	158
2021 Q2	$2.13M	Sell	40,000 -5,000	-11%	-$268K	0.02%	160
2021 Q1	$1.95M	Hold	45,000	–	–	0.02%	184
2020 Q4	$2.34M	Sell	45,000 -5,000	-10%	-$226K	0.03%	116
2020 Q3	$1.64M	Buy	+50,000	New	+$1.75M	0.02%	134

Other funds holding ZNTL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pentwater Capital Management's ZNTL Position: Q4 2021 in Review

Pentwater Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2021, closing a stake of 24,000 shares — an estimated $1.6M sold.

Pentwater Capital Management first reported a position in ZNTL in Q3 2020 and held it in 5 quarters. The position peaked at $2.34M in Q4 2020. 139 funds tracked by Wall St. Rank hold ZNTL as of Q4 2021.

Pentwater Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Pentwater Capital Management sold 24,000 Zentalis Pharmaceuticals shares in Q4 2021, an estimated $1.6M.
Pentwater Capital Management first reported a position in Zentalis Pharmaceuticals in Q3 2020 and held it in 5 quarters.
Pentwater Capital Management's Zentalis Pharmaceuticals position peaked at $2.34M in Q4 2020.
139 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2021.

Based on Pentwater Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.